QMS Medical Allied Services Releases Investor Presentation Highlighting Q1FY27 Growth
QMS Medical Allied Services reported Q1FY27 consolidated revenue of ₹56.9 crore, up 22% YoY. EBITDA grew 27% to ₹8.3 crore, with margins at 14.6%. PAT increased 25% to ₹4 crore. The company plans to acquire the remaining stake in Saarathi Healthcare by end of Q2FY27. Annual revenues grew to ₹172.9 crore in FY26.
The announcement is an investor presentation that details financial performance and strategic plans. While it shows positive growth, it does not involve a major new order, merger, acquisition, or significant operational change that would warrant a 'HIGH' impact. The information is material for investors.
The company reported significant year-on-year growth in revenue, EBITDA, and PAT, along with improved margins. The strategic acquisition plan and positive outlook on business segments contribute to a positive sentiment.
QMS Medical Allied Services Limited has released an investor presentation detailing its performance for the first quarter of FY27 (Q1FY27).
The company reported a strong start to the fiscal year, with consolidated revenue from operations growing by 22% year-on-year to ₹56.9 crore. EBITDA increased by 27% year-on-year to ₹8.3 crore, resulting in improved EBITDA margins of 14.6%. Profit After Tax (PAT) stood at ₹4 crore, marking a 25% year-on-year growth. The Product business showed healthy traction, supported by an expanding distribution network and product portfolio. The Services business emerged as a key growth engine, driven by deeper pharma partnerships and increasing adoption of Patient Support Programs (PSP).
During the quarter, QMS Medical Allied Services conducted 11,497 B2B health camps. The company also expects to acquire the balance stake in Saarathi Healthcare by the end of Q2FY27, which is expected to further strengthen its capabilities in disease management and PSPs.
The presentation also provides a detailed look at the company's annual financials, showcasing revenue growth from ₹104 crore in FY23 to ₹172.9 crore in FY26. Key financial metrics such as EBITDA, PAT, ROE, ROCE, and Debt to Equity ratio over the past four fiscal years are also presented.
What to do with a filing like this
QMS Medical Allied Services Limited filed this with the NSE as a statutory disclosure, categorised under investor presentation. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by QMS Medical Allied Services Limited. Read the original for the full detail.